CoChat

Well-Differentiated Gastric Tumors/Carcinomas

Open access
Ruszniewski, Philippe, Delle Fave, Gianfranco, Cadiot, Guillaume, Komminoth, Paul, Chung, Daniel, Kos-Kudla, Beata, Kianmanesh, Reza, Hochhauser, David, Arnold, Rudolf, Ahlman, Hakan, Pauwels, Stanislas, Kwekkeboom, Dik J., Rindi, Guido · 2006 · Neuroendocrinology
Cited by 154

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may however be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma.Current incidence of GETs is estimated at around 8% of digestive endocrine tumors [1,2,3]. Yearly age-adjusted incidence is around 0.2 per population of 100,000. GETs may occur in two different situations: sporadic GETs (type 3 tumors) are very rare tumors without predisposing factors for their development. They are most often located in the fundus/gastric corpus, but antral localization is possible. Gastric ECLomas develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. The latter may occur in two opposing conditions [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]: achlorhydria secondary to (auto-immune) atrophic fundic gastritis (type 1 tumors), or in response to hypergastrinemia resulting from tumoral secretion from gastrinomas (Zollinger-Ellison syndrome), mostly in patients presenting with multiple endocrine neoplasia type 1 (type 2 tumors). Table 1 summarizes the main characteristics of GETs.Type 1 tumors (ECLomas in the course of atrophic gastritis) occur mostly in women and are rarely responsible for symptoms [19]. They are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia or for macrocytic (but also iron deficiency) anemia [7, 12, 15, 17, 19]. ECLomas present frequently as multiple (2–10) polyps, usually <1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall [20]; the latter depends on tumor size [19, 21]. Type 2 tumors (ECLomas in the course of Zollinger-Ellison syndrome) are almost exclusively seen in MEN 1 patients [6,22,23,24], occurring in 23–29% of such cases (as compared with 1–3% in sporadic gastrinomas) [24,25,26]. They appear as small (<1–2 cm) polyps and may involve the entire fundic mucosa. They are generally asymptomatic.Type 3 tumors are usually solitary and mostly belong to WHO group 2: Ki 67 >2%, >2 cm in diameter with infiltrative growth; they occur mostly in men over 50 years of age [4,5,6, 19, 20, 27]. They may be discovered incidentally, but are often responsible for pain, weight loss, and iron-deficiency anemia. Atypical carcinoid syndrome due to histamine production is extremely rare (fig. 1).The yearly age-adjusted incidence of gastric type 1 and 2 endocrine tumors is approximately 0.2 per population of 100,000; however, these tumors are probably underdiagnosed. Type 1 tumors are the most common endocrine tumors of the stomach (70–85%) and they are usually benign (WHO group 1). Type 2 tumors, however, are much rarer; however up to 35% of cases are metastatic at presentation. Type 1 gastric carcinoids occur more frequently in women and 70–80% of tumors are classically diagnosed in the 5th and 7th decades, although with the more extensive use of endoscopy the age limit may be younger particularly in those patients with multiple autoimmune diseases. Clinical subtyping of ECL cell tumors (that is, distinction between type 1 and 2 tumors) is important and effective in patient management. Type 1 have almost universally good prognosis with rare tumor-related death at follow-up. Among type 2 gastric carcinoids, death due to metastatic gastric carcinoid is exceptional.Small gastric carcinoids are usually asymptomatic and very occasionally (<1%) patients may complain of flush and present the ‘atypical carcinoid syndrome’.Imaging techniques such as CT scan and MRI are of very limited value for small type 1 and 2 tumors. These lesions are recognized by upper GI endoscopy. Endoscopic ultrasonography (EUS) may help to determine tumor invasion in the depth of the gastric wall (table 2). In case of small (<1 cm) ECLomas, upper GI endoscopy is usually the only recommended imaging procedure.When there is a risk of metastases (table 1), and mainly in cases of sporadic tumors (type 3), an extensive search should be performed. EUS is useful in assessing regional lymph-node involvement and allows histological confirmation by fine-needle aspiration. Transabdominal ultrasonography, and mainly CT scan and MRI, have high sensitivity/specificity in looking for liver metastases. Somatostatin receptor scintigraphy (SRS) is recommended in these patients with well-differentiated tumors to search for liver, bone and lymph node metastases.Laboratory tests are of major interest, especially in patients with type 1 or 2 ECLomas. In these patients, basal serum gastrin levels should be determined and are always elevated [11, 28, 29], as well as serum chromogranin A levels [30]. Further tests should be performed depending on the clinical context. In the majority of the cases (type 1 tumors), no symptoms of ZES are present and upper GI endoscopy does not show any lesion related to pep

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000098007

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Ruszniewski, P., Delle Fave, G., Cadiot, G., Komminoth, P., Chung, D., Kos-Kudla, B., Kianmanesh, R., Hochhauser, D., Arnold, R., Ahlman, H., Pauwels, S., Kwekkeboom, D. J., & Rindi, G.
Venue
Neuroendocrinology
Publisher
S. Karger AG
Published
2006
Volume
84
Issue
3
Pages
158-164
ISSN
  • 0028-3835 (ISSN-L)
  • 1423-0194
OpenAlex
W1964997023
Cited by
154
References
1
FWCI
4.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.